

Delivering data-driven biological insights to guide drug discovery & development

CytoReason squeezes biology out of data, uncovering the cell/gene/molecule associations that are at the heart of treating disease - and the key to saving, extending and improving life. CytoReason's unmatched proprietary data, leading-edge machine learning technologies, unique cell-level models of disease & tissue and unrivalled analysis, are central to our proven ability to deliver data-driven biological insights that can increase the likelihood of R&D success: Speeding up development, reducing risk and providing commercial edge.

Biology. Data. Technology.

3 Key gaps CytoReason bridges to improve target discovery & drug development:

Biology: Delivery of a clear biological picture of disease/treatment at a cellular-level


Data: Access to, and optimal use of, proprietary and inaccessible human data

Technology: Technological ability to find & amplify critical signals from data

CytoReason extracts every drop of value from your R&D, discovering new: **Disease pathways & targets, mechanisms of action, disease & treatment biomarkers and indications.** Faster & more accurately than ever before.

Leveraging our unique cell-centered models and proprietary data and technologies, CytoReason:

- Rebuilds composition of active cells in disease & tissue
- Isolates signals and clears out irrelevant cellular activity
- Maps up/down-stream cells/gene/molecule associations
- Augments data beyond that studied
- Improves accuracy of biased data
- Compares & contrasts against other targets, diseases and patient populations



Our unique machine learning approach has uncovered new and validated discoveries...

Discovered:
New target and biomarkers
in melanoma micro-environment

Discovered:
New IL4 mechanism
of action in atopic dermatitis

Discovered:
Novel pre-treatment biomarkers
for IBD anti-TNF α therapy

Discovered:
355 previously unreported
cell/cytokine interactions

Discovered:
New Mouse to Man method
to convert mouse data to human conditions

Discovered:
First "Immune Age" prediction method
impacting drug & vaccine development

About CytoReason



Founded Oct '16
located in Tel Aviv




Based on 10 years' research from **Stanford and Technion**



Revenue funded
from inception



10 collaborations
with the likes of **Pfizer, GSK** and **Parker Institute for Cancer Immunotherapy**



CytoReason has long-term collaborations with:

Pfizer, GSK and other leading pharma companies: Covering a range of projects across their R&D groups such as in Inflammation & Immunology and Oncology diseases

Parker Institute for Cancer Immunotherapy: Focusing on cancer immunotherapy, clinical trials platform and identification of biomarkers

Summit Pharmaceuticals International: Focusing on the Japanese market

CytoReason: Unlocking novel disease targets, mechanisms of action, patient stratification biomarkers, indication prioritization and clinical trial risk mitigation